In the News
Summer Symposium: "Understanding Metastasis"
The Koch Institute Symposium, held each spring at MIT, focuses on cutting edge research that holds new promise for understanding and conquering human disease. more >>
Read about the launch of the Koch Institute in our latest brochure. download pdf >>
KI Member Robert Weinberg's lab reports in Cell how a small RNA suppresses metastasis
High levels of a tiny fragment of RNA appear to suppress the spread of breast cancer in mice. Measuring levels of this so-called microRNA, which is also associated with metastatic breast cancer in humans, may more accurately predict the likelihood of metastasis (which accounts for 90 percent of cancer-related deaths) and ultimately help determine patient outcomes. more >>
KI's Sangeeta Bhatia and colleagues awarded Stand Up 2 Cancer (SU2C) funding
Stand Up To Cancer (SU2C), the Entertainment Industry Foundation's charitable initiative supporting groundbreaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, has reached a significant milestone, awarding the first round of three-year grants – that total $73.6 million – to five multi-disciplinary, multi-institutional research "Dream Teams." more >>
Tyler Jacks on The Today Show announces Stand Up 2 Cancer (SU2C) funding
Five "dream teams" awarded $73M in funding to support highly collaborative projects. more >>
Wellcome Trust and MIT launch new interdisciplinary research fellowship program
The Wellcome Trust announced on May 7 the establishment of a new program at MIT that will fund postdoctoral fellows to do research at the interfaces between biology/medicine, computation, the physical sciences and engineering. Postdoctoral researchers in the program will be funded for two to three years at MIT followed by one to two years in the United Kingdom. The program expects to enroll five scientists per year, starting this fall. more >>
Implantable monitoring device can detect tumor growth
Biopsies offer a snapshot of a tumor at a single moment in time. Monitoring a tumor for weeks or months after the biopsy, tracking its growth and how it responds to treatment, would be much more valuable, says KI scientist Michael Cima, who has developed the first implantable device that can do just that. more >>
Gold "nanorod" formulations show promise in cancer detection and treatment
It has long been known that heat is an effective weapon against tumor cells. However, it's difficult to heat patients' tumors without damaging nearby tissues. Now, MIT researchers have developed tiny gold particles that can home in on tumors, and then, by absorbing energy from near-infrared light and emitting it as heat, destroy tumors with minimal side effects. more >>
The Economist reports on medicine going digital
KI research is paving the way for a revolutionary convergence of engineering and biology. more >>
KI Director is elected to prestigious National Academy of Sciences
Tyler Jacks is one of 72 newly elected to NAS for distinguished and on-going achievements in original science. more >>
"Fuzzy logic" used by MIT team to predict potential treatment responses
Living cells are bombarded with messages from the outside world – hormones and other chemicals tell them to grow, migrate, die or do nothing. Inside the cell, complex signaling networks interpret these cues and make life-and-death decisions. Using a "fuzzy logic" approach, a team of MIT biological engineers has created a new model that reveals different and novel information about these inner cell workings than traditional computational models. more >>
New biomarker may lead to a test that can predict aggressive cancer
Researchers have developed a test that could help doctors precisely identify which breast cancer patients should receive aggressive therapy, thereby sparing many women at low risk for metastatic disease from undergoing unnecessary and potentially dangerous treatment. The researchers, including KI scientist Frank Gertler, developed the test based on an earlier finding that the co-mingling of three cell types can predict whether localized breast cancer will metastasize, or spread throughout the body. more >>
Forbes reports on the emerging role of artificial livers in developing new drugs
Maybe liver cells have the right to be such temperamental divas. They do a lot, such as building thousands of proteins, breaking down toxins, storing vitamins, metabolizing carbohydrates and helping digest fats. But take them out of the body, and they simply refuse to cooperate. At least so far. And so that's exactly what Sangeeta Bhatia, an MIT engineering professor who also has her M.D., wants them to do—function better outside of the body. If she can convince them to do that, a new vista of medical opportunities opens up, including better toxicity tests and even more replacement organs. more >>
KI researchers report on a major advance in reprogramming skin cells into stem cells
Researchers have developed a novel method of removing potential cancer-causing genes during the reprogramming of skin cells from Parkinson's disease patients into an embryonic-stem-cell-like state. Scientists were then able to use the resulting induced pluripotent stem (iPS) cells to derive dopamine-producing neurons, the cell type that degenerates in Parkinson's disease patients. more >>
Bhatia Lab student wins Lemelson-MIT prize
MIT graduate student and biomedical engineer Geoffrey von Maltzahn is this year's winner of the $30,000 Lemelson-MIT Student Prize for his promising innovations in the area of cancer therapy. The 28-year-old PhD candidate in the Harvard-MIT Division of Health Sciences and Technology (HST) was selected specifically for two of his inventions in nanomedicine: a new class of cancer therapeutics and a new paradigm for enhancing drug delivery to tumors. more >>
Major KI milestone hit on time and on budget
Highlights of the Topping-Off Ceremony for The David H. Koch Institute for Integrative Cancer Research at MIT on Feb. 19, 2009. video >>
KI faculty share latest technologies at recent World Economic Forum IdeasLab Annual Meeting
Sangeeta Bhatia and Michael Cima shared their latest research at an international meeting in Davos-Klosters, Switzerland. more >>
Using RNAi to tackle ovarian cancer
Small RNA molecules can effectively keep ovarian tumors from growing and spreading in mice, according to a team of researchers from MIT, the Lankenau Institute for Medical Research and Alnylam Pharmaceuticals. more >>
KI professor among 10 "Women to Watch"
Sangeeta Bhatia, a professor of electrical engineering and health sciences and technology, was named one of the 10 "Women to Watch" on Jan. 23 by the newspaper Mass High Tech. Bhatia was cited with nine others for leading their respective fields and for outstanding dedication to technology, entrepreneurship, lifelong learning and civic responsibility. more >>
Therapeutic Antibodies
Researchers have found that antibodies do not need a particular sugar attachment long believed to be essential to their function, a discovery that could make producing therapeutic antibodies much easier and cheaper in the future. more >>
Too much of a good thing: Cells with extra chromosomes share detrimental traits
Mammalian cells with extra chromosomes share some common traits that could be exploited to develop cancer treatments, according to MIT biologists. more >>
How to win the war against cancer
The power of massive, integrated programs must be brought to bear. more >>
New KI computational models to individualize cancer treatment
In Cell, KI researcher describe how computer simulations can reveal the inner workings and vulnerabilities of a cancer. The results reveal new ways in which cells process chemical information and could indicate how to maximize the effectiveness of disease treatments such as chemotherapy. more >>
Prostate cancers can escape immunity
KI researchers describe potent immuno-suppressive activity of prostate cancer microenvironment. more >>
TIME Magazine takes critical look at new trends in cancer research
KI's integrative research approach highlighted as a leading example. more >>
Progress made in predicting patients' response to chemo
Koch Institute plays important role in uncovering why people react differently to chemotherapy. more >>
New NIH EUREKA grant awarded to Koch Institute Faculty Member
New MEMS chip for cell sizing seen as revolutionary science. more >>
KI nano-delivery systems continue to advance
Alnylam and KI collaborators publish new research on RNAi mediated gene silencing of PCSK9, a genetically validated regulator of LDL metabolism. more >>
Ahead of the curve on cancer research
MIT engineers and biologists seek to optimize potential treatments. more >>
Mapping new RNA expression changes in cancer cells
Published in Science, KI researcher define novel changes in 3'UTR and microRNAs in cancer cells. more >>
Tyler Jacks on the new David H. Koch Institute
Tyler Jacks, director of the Koch Institute, discusses his vision for the new center and the cancer research that will take place there in this interview with MIT News Office writer Anne Trafton. more >>
David H. Koch gives $100 million to MIT for cancer research
MIT has announced a $100 million gift from Koch Industries executive and MIT alumnus David H. Koch that will usher in new paradigms in highly integrative cancer research. The gift will bring together MIT scientists and engineers under one roof to develop new and powerful ways to detect, diagnose, treat, and manage this often deadly disease. more >>
Langer wins Millennium Technology Prize
MIT Institute Professor Robert Langer has won the Millennium Technology Prize, the world's largest award for technology innovation. more >>
Team develops safe, effective RNA interference technique
A team of researchers from MIT and Alnylam Pharmaceuticals has developed safe and effective methods to perform RNA interference, a therapy that holds great promise for treating a variety of diseases including cancer and hepatitis. more >>
MIT breaks ground for Koch institute
MIT broke ground on Friday for the new David H. Koch Institute for Integrative Cancer Research, a facility that its director, Tyler Jacks, said will usher in "the next generation in cancer research." more >>
Uncovering a protective role of microRNA
Snippets of genetic material that have been linked to cancer also play a critical role in normal embryonic development in mice, according to a new paper from MIT cancer biologists. more >>
Cancer Study shows power of interdisciplinary approach
A UCLA cancer study reported in this month's Nature Nanotechnology validates earlier work by MIT engineers, and is emblematic of an explosion in research at the intersections of engineering, the life sciences and medicine, according to MIT Dean of Engineering Subra Suresh. more >>
'Micro' livers could aid drug screening
MIT researchers have devised a novel way to create tiny colonies of living human liver cells that model the full-sized organ. The work could allow better screening of new drugs that are potentially harmful to the liver and reduce the costs associated with their development. more >>
Remote-control nanoparticles deliver drugs directly into tumors
MIT scientists have devised remotely controlled nanoparticles that, when pulsed with an electromagnetic field, release drugs to attack tumors. The innovation, reported in the Nov. 15 online issue of Advanced Materials, could lead to the improved diagnosis and targeted treatment of cancer. more >>
The Cantoni Memorial Lecture Series: Biology & Biochemistry of Small RNA
MIT works toward novel therapeutic device
MIT and University of Rochester researchers report important advances toward a therapeutic device that has the potential to capture cells as they flow through the blood stream and treat them. Among other applications, such a device could zap cancer cells spreading to other tissues, or signal stem cells to differentiate. more >>
Amon, Golub win cancer prize: Paul Marks Prize recognizes significant research contributions
MIT Professor Angelika Amon and Todd R. Golub of the Broad Institute of MIT and Harvard will share the 2007 Paul Marks Prize for Cancer Research, an award of $150,000, with Gregory J. Hannon from Cold Spring Harbor Laboratory. more >>
